Overall survival of patients with AML and MDS-EB (n = 2200). (A) Overall survival of AML/MDS-EB patients by the ELN 2017 risk classification. Patients in the adverse risk category are segregated by TP53 wild-type and TP53 mutant. (B) Overall survival of AML and MDS-EB disease classification at diagnosis stratified according to patients with TP53 wild-type and TP53 mutant.